Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2016-000588-17-ES
EUCTR2016-000588-17-ESActive, not recruitingPhase 1

A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426) - Pembrolizumab plus axitinib vs. sunitinib monotherapy in advanced/metastatic renal cell carcinoma

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.0 sites840 target enrollmentStarted: August 5, 2016Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
840
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •- Be > or = 18 years of age on day of signing informed consent
  • •- Have histologically confirmed diagnosis of RCC with clear cell component with or without sarcomatoid features
  • •- Have locally advanced/metastatic disease (i.e., Stage IV RCC per American Joint Committee on Cancer) or have recurrent disease
  • •- Have measurable disease per RECIST 1.1 as assessed by the investigator /site radiologist. Target lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions
  • •- Have received no prior systemic therapy for advanced RCC
  • •- Provide tumor tissue for biomarker analysis
  • •- Demonstrate adequate organ function
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 400
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 440

Exclusion Criteria

  • •- Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to randomization
  • •- Has had major surgery within 4 weeks prior to randomization or radiation therapy within 2 weeks prior to randomization, or who has not recovered (i.e., < or = Grade 1 or at baseline) from AEs due to prior treatment
  • •- Has had prior treatment with any anti-PD-1, or PD-L1, or PD-L2 agent or an antibody targeting any other immune-regulatory receptors or mechanisms. Examples of such antibodies include (but are not limited to) antibodies against IDO, PD-L1, IL-2R, and GITR
  • •- Has received prior therapy with VEGF/VEGFR or mTOR targeting agents
  • •- Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to randomization
  • •- Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic or immunosuppressive agents
  • •- Has a known additional malignancy that has progressed or has required active treatment in the last 3 years
  • •- Has known active CNS metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable
  • •- Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis
  • •- Has a clinically significant gastrointestinal (GI) abnormality including: Inability to take oral medication, Requirement for IV alimentation, Prior surgical procedures affecting absorption including total gastric resection, Treatment for active peptic ulcer within the past 6 months, Active GI bleeding, as evidenced by hematemesis, hematochezia or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy, Intraluminal metastatic lesion with suspected bleeding, inflammatory bowel disease, ulcerative colitis or other GI condition associated with increased risk of perforation, or history of GI perforation, Malabsorption syndromes, Inflammatory bowel disease
  • •- Has QT interval corrected for heart rate (QTc) > or = 480 msec
  • •- Has a history of any of the following cardiovascular conditions within 12 months of screening: Myocardial infarction, Unstable angina pectoris, Cardiac angioplasty or stenting, Coronary/peripheral artery bypass graft, Class III or IV congestive heart failure per New York Heart Association, Cerebrovascular accident or transient ischemic attack
  • •- Has a history of deep vein thrombosis or pulmonary embolism within 6 months of screening
  • •- Has poorly controlled hypertension defined as systolic blood pressure (SBP) > or = 150 mm Hg and/or diastolic blood pressure (DBP) > or = 90 mm Hg
  • •- Has evidence of inadequate wound healing
  • •- Has active bleeding disorder or other history of significant bleeding episodes within 30 days of randomization
  • •- Has hemoptysis within 6 weeks prior to randomization
  • •- Has current use or anticipated need for treatment with drugs or foods that are known strong cytochrome P450 (CYP3A4/5) inhibitors
  • •- Has current use or anticipated need for treatment with drugs that are known strong CYP3A4/5 inducers
  • •- Has had a prior solid organ transplant

Investigators

Similar Trials

Active, not recruiting
Phase 1
A clinical study of Pembrolizumab plus axitinib vs. sunitinib in advanced kidney cancerAdvanced Kidney CancerMedDRA version: 20.1Level: LLTClassification code 10023400Term: Kidney cancerSystem Organ Class: 100000004864
EUCTR2016-000588-17-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.840
Active, not recruiting
Phase 1
A clinical study of Pembrolizumab plus axitinib vs. sunitinib in advanced kidney cancerAdvanced Kidney CancerMedDRA version: 19.0Level: LLTClassification code 10023400Term: Kidney cancerSystem Organ Class: 100000004864
EUCTR2016-000588-17-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.840
Active, not recruiting
Phase 1
A clinical study of Pembrolizumab plus axitinib vs. sunitinib in advanced kidney cancer
EUCTR2016-000588-17-IEMerck Sharp & Dohme LLC840
Active, not recruiting
Phase 1
A clinical study of Pembrolizumab plus axitinib vs. sunitinib in advanced kidney cancerAdvanced Kidney CancerMedDRA version: 20.1Level: LLTClassification code 10023400Term: Kidney cancerSystem Organ Class: 100000004864
EUCTR2016-000588-17-CZMerck Sharp & Dohme Corp.840
Active, not recruiting
Phase 1
A clinical study of Pembrolizumab plus axitinib vs. sunitinib in advanced kidney cancerAdvanced Kidney CancerMedDRA version: 20.1Level: LLTClassification code 10023400Term: Kidney cancerSystem Organ Class: 100000004864
EUCTR2016-000588-17-GBMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.840